Drug interactions with statins

Acta Pharmaceutica

Volumn 63, Issue 3, 2013, Pages 277-293

  Causevic Ramosevac, Anida ^a   Semiz, Sabina ^b,c  

^a Joint Stock Company   (Bosnia and Herzegovina)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^c INTERNATIONAL UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

adverse effects; cytochrome P450 (CYP) enzymes; drug interactions; drug transporters; statins

Indexed keywords

AMIODARONE; ATORVASTATIN; AZELNIDIPINE; AZITHROMYCIN; BENIDIPINE; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; DILTIAZEM; ERLOTINIB; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NELFINAVIR; NIFEDIPINE; ORGANIC ANION TRANSPORTER 1; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TELITHROMYCIN; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; MYOPATHY; ORANGE JUICE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84887338132     PISSN: 13300075     EISSN: 18469558     Source Type: Journal    
DOI: 10.2478/acph-2013-0022     Document Type: Review

References (131)

1. R. J. Herman, Drug interactions and the statins, CMAJ 161 (1999) 1281-1286
2. Cardiovascular Drugs, in Martindale: The Complete Drug Reference, 36th ed. (Ed. S. C. Sweetman), Pharmaceutical Press, London 2009, pp. 1155-1434
3. T. Uno, K. Sugimoto, K. Sugawara and T. Tateishi, The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazol, Ther. Drug Monit. 30 (2008) 276-281; DOI: 10.1097/FTD.0b013e31816e2d8e
4. C. Bolego, R. Baetta, S. Bellosta, A. Corsini and R. Paoletti, Safety considerations for statins, Curr. Opin. Lipidol. 13 (2002) 637-644
5. H. M. Devold, E. Molden, S. Skurtveit and K. Furu, Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy, Br. J. Clin. Pharmacol. 67 (2009) 234-241; DOI: 10.1111/j.1365-2125. 2008.03345.x
6. E. Molden, K. S. Andersson and D. Jacobsen, Interactions between statins and macrolide antibiotics, Tidsskr. Nor. Laegeforen 127 (2007) 1660-1661
7. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paolett and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther. 84 (1999) 413-428
8. C. M. White, A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin, J. Clin. Pharmacol. 42 (2002) 963-970
9. R. Bhindi, O. Ormerod, J. Newton, A. P. Banning and L. Tesla, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101 (2008) 915-925; DOI: 10.1093/qjmed/ hcn089
10. P. J. Neuvonen, M. Niemi and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance, Clin. Pharmacol. Ther. 80 (2006) 565-581
11. K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang, Membrane transporters in drug development, Nat. Rev. Drug Discov. 9 (2010) 215-236; DOI: 10.1038/nrd3028
12. M. Karlgren, G. Ahlin, C. A. Bergström, R. Svensson, J. Palm and P. Artursson, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions, Pharm. Res. 29 (2012) 411-426; DOI: 10.1007/s11095-011-0564-9
13. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop and R. Collins, SLCO1B1 variants and statin-induced myopathy - a genomewide study, N. Engl. J. Med. 359 (2008) 789-799; DOI: 10.1056/ NEJMoa0801936
14. D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury and G. S. Ginsburg, The SLCO1B15 genetic variant is associated with statin-induced side effects, J. Am. Coll. Cardiol. 54 (2009) 1609-1616; DOI: 10.1016/j.jacc.2009.04.053
15. J. P. F. Bai, Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics, Drug Metab. Pharmacokin. 25 (2010) 62-71
16. J. Mwinyi, A. Johne, S. Bauer, I. Roots and T. Gerloff, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetic, Clin. Pharmacol. Ther. 75 (2004) 415-421
17. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum and K. T. Kivistö, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics 14 (2004) 429-440
18. Y. Shitara, Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions, Drug Metab. Pharmacokin. 26 (2011) 220-227; DOI: 10.2133/dmpk.DMPK-10-RV-094
19. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa and K. Chib, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokin. 19 (2004) 453-455
20. Y. Y. Lau, H. Okochi, Y. Huang and L. Z. Benet, Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems, J. Pharmacol. Exp. Ther. 316 (2006) 762-771
21. G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman and Y. Elhawi, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir, J. Am. Board. Fam. Med. 20 (2007) 411-416
22. V. Borders-Hemphill, Concurrent use of statins and amiodarone, Consult. Pharm. 24 (2009) 372-379
23. S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann. Pharmacother. 42 (2008) 1037-1047; DOI: 10.1345/aph.1K628
24. D. Williams and J. Freely, Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors, Clin. Pharmacokinet. 41 (2002) 343-370
25. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (2004) III50-III57; DOI: 10.1161/01.CIR.0000131519.15067.1f
26. K. Ohyama, M. Nakajima, M. Suzuki, N. Shimada, H. Yamazaki and T. Yokoi, Inhibitory effects of amiodarone and its N-desethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions, Br. J. Clin. Pharmacol. 49 (2000) 244-253
27. U. M. Chouhan, S. Chakrabarti and L. J. Millward, Simvastatin interaction with clarithromycin and amiodarone causing myositis, Ann. Pharmacother. 39 (2005) 1760-1761
28. A. Marot, J. Morelle, V. A. Chouinard, M. Jadoul, M. Lambert and N. Demoulin, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: Acase report and review of the literature, Acta Clin. Belg. 66 (2011) 134-136
29. B. Ricaurte, A. Guirguis, H. C. Taylor and D. Zabriskie, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity, Ann. Pharmacother. 40 (2006) 753-757
30. A. Alsheikh-Ali and R. Karas, Adverse events with concomitant amiodarone and statin therapy, Prev. Cardiol. 8 (2005) 95-97
31. S. Karimi, A. Hough, C. Beckey and D. Parra, Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center, J. Manag. Care Pharm. 16 (2010) 472-481
32. DRUGDEX®/MICROMEDEX®. Statins. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2012. Retrieved from:http://www.thomsonhc.com/ home/dispatch (accessed July 6, 2012)
33. G. W. Amsden, O. Kuye and G. C. Wei, A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers, J. Clin. Pharmacol. 42 (2002) 444-449
34. G. W. Amsden, Macrolides versus azalides: Adrug interaction update, Ann. Pharmacother. 29 (1995) 906-917
35. M. P. Pai, D. M. Graci and G. W. Amsden, Macrolide drug interactions: an update, Ann. Pharmacother. 34 (2000) 495-513
36. J. W. Grunden and K. A. Fisher, Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin, Ann. Pharmacother. 31 (1997) 859-863
37. M. Z. Skrabal, J. A. Stading, C. A. Cannella and M. S. Monaghan, Two cases of rhabdomyolysis associated with high-dose simvastatin, Am. J. Health. Syst. Pharm. 60 (2003) 578-581
38. J. Strandell, A. Bate, S. Hägg and I. R. Edwards, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction, Br. J. Clin. Pharmacol. 68 (2009) 427-434; DOI: 10.1111/j. 1365-2125.2009.03473.x
39. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood and G. R. Wilkinson, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res. 16 (1999) 408-414
40. C. Marzolini, E. Paus, T. Buclin and R. B. Kim, Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance, Clin. Pharmacol. Ther. 75 (2004) 13-33
41. S. Eberl, I. Bachmakov, F. Dörje and M. F. Fromm, The effect of macrolide antibiotics on the function of the drug transporter P-glycoprotein, Naunyn-Schmiedeberg's Arch. Pharmacol. 371 (2005) R145
42. J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack and W. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction, Br. J. Clin. Pharmacol. 56 (2003) 32-38
43. T. Jacobson, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors, Am. J. Cardiol. 94 (2004) 1140-1146
44. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dörje, M. F. Fromm and J. König, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3, Drug Metab. Dispos. 35 (2007) 779-786
45. M. Hirano, K. Maeda, Y. Shitara and Y. Sugiyama, Drug-drug interaction between pitavastatin and various drugs via OATP1B1, Drug Metab. Dispos. 34 (2006) 1229-1236
46. R. D. Sawant, Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin, Can. J. Clin. Pharmacol. 16 (2009) 78-79
47. M. Ishigami, M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito and Y. Sugiyama, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions, Pharm. Res. 18 (2001) 622-631
48. K. T. Kivistö, T. Kantola and P. J. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, Br. J. Clin. Pharmacol. 46 (1998) 49-53
49. K. Akram, S. Rao and M. Parker, A lesson for everyone in drug-drug interactions (letter), Int. J. Cardiol. 118 (2007) 19-20
50. R. Gilad and Y. Lampl, Rhabdomyolysis induced by simvastatin and ketoconazole treatment, Clin. Neuropharmacol. 22 (1999) 295-297
51. H. Itakura, D. Vaughn, D. Haller and P. O'Dwyer, Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer, J. Urol. 169 (2003) 613; DOI: 10. 1016/S0022-5347(05)63967-5
52. C. Stein, S. Goel and R. Ghavamian, Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy, Invest. New Drugs 25 (2007) 277-278
53. O. Findling, N. Meier, J. Sellner, K. Nedeltchev and M. Arnold, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole, Neurology 71 (2008) 34-37; DOI: 10.1212/01.wnl.0000327566.57661.09
54. C. C. Franz, M. Bruggisser, S. Krähenbühl and A. E. Rätz Bravo, Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole, Praxis (Bern 1994) 100 (2011) 273-284; DOI: 10.1024/1661-8157/ a000491
55. R. Hazin, J. Y. Abuzetun, M. Suker and J. Porter, Rhabdomyolysis induced by simvastatin-fluconazole combination, J. Natl. Med. Assoc. 100 (2008) 444-446
56. A. Shaukat, M. Benekli, G. D. Vladutiu, J. L. Slack, M. Wetzler and M. R. Baer, Simvastatin-fluconazole causing rhabdomyolysis, Ann. Pharmacother. 37 (2003) 1032-1035
57. N. E. Azie, D. C. Brater, P. A. Becker, D. R. Jones and S. D. Hall, The interaction of diltiazem with lovastatin and pravastatin, Clin. Pharmacol. Ther. 64 (1998) 369-377
58. O. Mousa, D. C. Brater, K. J. Sunblad and S. D. Hall, The interaction of diltiazem with simvastatin, Clin. Pharmacol. Ther. 67 (2000) 267-274
59. Y. Sugiyama, N. Mimura, T. Kuwabara, H. Kobayashi, J. Ushiki and E. Fuse, Effect of benidipine on simvastatin metabolism in human liver microsomes, Drug Metab. Pharmacokinet. 22 (2007) 199-205
60. J. J. Lewin, J. M. Nappi and M. H. Taylor, Rhabdomyolysis with concurrent atorvastatin and diltiazem, Ann. Pharmacother. 36 (2002) 1546-1549
61. R. Peces and A. Pobes, Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem, Nephron. 89 (2001) 117-118
62. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin and T. A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, Br. J. Clin. Pharmacol. 47 (1999) 291-298
63. M. Jasiñska, J. Owczarek and D. Orszulak-Michalak, The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study, Acta Pol. Pharm. 63 (2006) 386-390
64. T. Kantola, K. T. Kivisto and P. J. Neuvonen, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 64 (1998) 177-182
65. H. Satoh, F. Yamashita, M. Tsujimoto, H. Murakami, N. Koyabu, H. Ohtani and Y. Sawada, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B, Drug Metab. Dispos. 33 (2005) 518-523
66. P. Li, P. S. Callery, L. S. Gan and S. K. Balani, Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction, Drug Metab. Dispos. 35 (2007) 1203-1208
67. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin, Clin. Pharmacol. Ther. 66 (1999) 118-127
68. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors, Clin. Pharmacol. Ther. 64 (1998) 477-483
69. J. J. Lilja, M. Neuvonen and P. J. Neuvonen, Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin, Br. J. Clin. Pharmacol. 58 (2004) 56-60
70. I. Fukazawa, N. Uchida, E. Uchida and H. Yasuhara, Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese, Br. J. Clin. Pharmacol. 57 (2003) 448-455
71. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko and A. Fujimura, Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin, Br. J. Pharmacol. 60 (2005) 494-497
72. Y. Koitabashi, T. Kumai, N. Matsumoto and M. Watanabe, Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects, Life Sci. 78 (2006) 2852-2859
73. A. V. Sorokin, B. Duncan, R. Panetta and P. D. Thompson, Rhabdomyolysis associated with pomegranate juice consumption, Am. J. Cardiol. 98 (2006) 705-706
74. T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima and Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine, J. Clin. Ther. Med. 19 (2003) 381-389
75. Y. Shitara, T. Itoh, H. Sato, A. P. Li and Y. Sugiyam, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A, J. Pharmacol. Exp. Ther. 304 (2003) 610-616
76. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass and D. W. Schneck, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther. 76 (2004) 167-177
77. J. Tong, G. Laport and R. Lowsky, Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma, Bone Marrow Transplant. 36 (2005) 739-740
78. A. Lasocki, B. Vote, R. Fassett and E. Zamir, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis, Ocul. Immunol. Inflamm. 15 (2007) 345-346
79. S. Vives, M. Batlle, E. Montané and J. M. Ribera, Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient, Med. Clin. (Barc). 131 (2008) 676
80. J. W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. März, D. Seidel, S. Schüler and W. Gross, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A, Int. J. Clin. Pharmacol. Therapeut. 40 (2002) 439-450
81. M. Veeraputhiran and M. Sundermeyer, Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin, Clin. Lung Cancer 9 (2008) 232-234; DOI: 10.3816/CLC. 2008.n.036
82. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis and C. S. Flordellis, Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients, Indian J. Pharmacol. 43 (2011) 385-388; DOI: 10.4103/0253-7613.83106
83. R. H. Jacobson, P. Wang and C. J. Glueck, Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone, JAMA. 277 (1997) 296-297
84. N. S. Karnik and J. R. Maldonado, Antidepressant and statin interactions: Areview and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminiti, Psychosomatics 46 (2005) 565-568
85. Serzone (nefazodone hydrochloride) US prescribing information, Bristol-Myers Squibb Company, January 2005
86. C. B. Hare, M. P. Vu, C. Grunfeld and H. W. Lampiris, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death, Clin. Infect. Dis. 35 (2002) 111-112
87. P. E. Sax, Strategies for management and treatment of dyslipidemia in HIV/AIDS, AIDS Care 18 (2006) 149-157
88. P. H. Hsyu, M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis and B. M. Kerr, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin, Antimicrob. Agents Chemother. 4 (2001) 3445-3450
89. R. A. Carr, A. K. Andre, R. J. Bertz, W. Lam, M. Chang, P. Chen, P. Williams, B. Bernstein and E. Sun, Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin, 40th ICAAC, Toronto, September 2000, presentation 1644
90. C. J. Fichtenbaum, J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, F. Aweeka and NIAID AIDS Clinical Trials Group, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, AIDS 16 (2002) 569-577
91. J. A. Aberg, S. L. Rosenkranz, C. J. Fichtenbaum, B. L. Alston, S. W. Brobst, Y. Segal, J. G. Gerber and ACTG A5108 team, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108, AIDS 20 (2006) 725-729
92. P. A. Pham, C. J. la Porte L. S., Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner and D. W. Cameron, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers, Antimicrob. Agents Chemother. 53 (2009) 4385-4392; DOI: 10.1128/AAC.00449-09
93. R. Stern, R. Abel, G. L. Gibson and J. Besserer, Atorvastatin does not alter the anticoagulant activity of warfarin, J. Clin. Pharmacol. 37 (1997) 1062-1064
94. H. Hickmott, H. Wynne and F. Kamali, The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements, Thromb. Haemost. 89 (2003) 949-950
95. J. C. Lin, M. K. Ito, S. N. Stolley, A. P. Morreale and D. B. Marcus, The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, J. Clin. Pharmacol. 39 (1999) 86-90
96. E. A. Sconce, T. I. Khan, A. K. Daly, H. A. Wynne and F. Kamali, The impact of simvastatin on warfarin disposition and dose requirements, J. Thromb. Haemost. 4 (2006) 1422-1424
97. T. Westergren, P. Johansson and E. Molden, Probable warfarin-simvastatin interaction, Ann. Pharmacother. 41 (2007) 1292-1295
98. S. Ahmad, Lovastatin warfarin interaction, Arch. Intern. Med. 150 (1990) 2407
99. H. S. Hoffman, The interaction of lovastatin and warfarin, Conn. Med. 56 (1992) 107
100. E. A. Iliadis and M. F. Konwinski, Lovastatin during warfarin therapy resulting in bleeding, PA Med. 98 (1995) 31
101. S. S. Kline and C. C. Harrell, Potential warfarin-fluvastatin interaction, Ann. Pharmacother. 31 (1997) 790
102. L. E. Trilli, C. L. Kelley, S. L. Aspinall and B. A. Kroner, Potential interaction between warfarin and fluvastatin, Ann. Pharmacother. 30 (1996) 1399-1402
103. M. J. Murphy and M. H. Dominiczak, Efficacy of statin therapy: possible effect of phenytoin, Postgrad. Med. J. 75 (1999) 359-360
104. K. M. Tan, J. G. Kelly and K. McGarry, Statins and phenytoin interact - a case history, Br. J. Clin. Pharmacol. 65 (2008) 147-148
105. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 68 (2000) 592-597
106. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects, Br. J. Clin. Pharmacol. 57 (2004) 181-187
107. R. Eggertsen, A. Andreasson and L. Andrén, Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin, Scand. J. Prim. Health Care 25 (2007)
108. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada, M. Arakawa, K. Sakamoto, M. Masada, I. Miyamori and A. Fujimura, Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin, Clin. Pharmacol. Ther. 70 (2001) 518-524
109. W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. Carville, K. E. Guyer and E. R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: Anew drug-drug interaction, Circulation 107 (2003) 32-37
110. A. Blagojevic, J. A. Delaney, L. E. Lévesque, N. Dendukuri, J. F. Boivin and J. M. Brophy, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: Acohort study, Pharmacoepidemiol. Drug Saf. 18 (2009) 362-369; DOI: 10.1002/pds.1716
111. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schömig and A. Kastrati, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting, Eur. Heart J. 25 (2004) 1898-1902
112. J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos and A. D. Tselepis, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes, Circulation 109 (2004) 1335-1338
113. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg and M. Gawaz, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation 108 (2003) 2195-2197
114. J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K. H. Mak, K. Fox and E. J. Topol, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J. Am. Coll. Cardiol. 50 (2007) 291-295
115. V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J. F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O'Connor and C. H. Hennekens, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch. Intern. Med. 164 (2004) 2051-2057
116. P. Vinholt, T. S. Poulsen, L. Korsholm, S. R. Kristensen, J. Hallas, P. Damkier and H. Mickley, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease, Thromb. Haemost. 94 (2005) 438-443
117. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D. A. Tsakiris and S. Krähenbühl, Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro, Br. J. Pharmacol. 161 (2010) 393-404; DOI: 10.1111/j.1476-5381.2010.00881.x
118. L. R. Whitfield, A. R. Porcari, C. Alvey, R. Abel, W. Bullen and D. Hartman, Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin, J. Clin. Pharmacol. 51 (2011) 378-388; DOI: 10.1177/ 0091270010366446
119. J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman and P. J. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes, Drug Metab. Dispos. 30 (2002) 1352-1356
120. X. Wen, J. S. Wang, J. T. Backman, K. T. Kivistö and P. J. Neuvonen, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9, Drug Metab. Dispos. 29 (2001) 1359-1361
121. H. Fujino, I. Yamada, S. Shimada, M. Hirano, Y. Tsunenari and J. Kojima, Interaction between fibrates and statins - metabolic interactions with gemfibrozil, Drug Metabol. Drug Interact. 19 (2003) 161-176
122. J. T. Backman, C. Kyrklund, K. T. Kivistö, J. S. Wang and P. J. Neuvonen, Plasma concentrations of active simvastatin acid are increased by gemfibrozil, Clin. Pharmacol. Ther. 68 (2000) 122-129
123. T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams and C. M. Loi, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid, Drug Metab. Dispos. 35 (2007) 1315-1324
124. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate, Clin. Pharmacol. Ther. 69 (2001) 340-345
125. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance, Clin. Pharmacol. Ther. 73 (2003) 538-544
126. P. Mathew, T. Cuddy, W. G. Tracewell and D. Salazar, An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers, Clin. Pharmacol. Ther. 75 (2004) 33
127. J. D. Spence, C. E. Munoz, L. Hendricks, L. Latchinian and H. E. Khouri, Pharmacokinetics of the combination of fluvastatin and gemfibrozil, Am. J. Cardiol. 76 (1995) 80A-83A
128. N. Bizzaro, E. Bagolin, L. Milani, C. Cereser and B. Finco, Massive rhabdomyolysis and simvastatin, Clin. Chem. 38 (1992) 1504
129. R. A. Boyd, R. H. Stern, B. H. Stewart, X. Wu, E. L. Reyner, E. A. Zegarac, E. J. Randinitis and L. Whitfield, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion, J. Clin. Pharmacol. 40 (2000) 91-98
130. C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. März, J. P. Reckless and E. A. Stein, Risk for myopathy with statin therapy in high-risk patients, Arch. Intern. Med. 163 (2003) 553-564
131. P. D. Thompson, P. Clarkson and R. H. Karas, Statin-associated myopathy, JAMA 289 (2003) 1681-1690